Orchid Pharma held its 33rd Annual General Meeting on September 29, 2026, where members adopted the revised standalone and consolidated financial statements for the fiscal year ended March 31, 2026. The meeting, conducted via video conferencing, also saw the approval of several key governance and operational resolutions.

The company’s statutory auditors issued a clean report on the standalone financial statements. However, the consolidated auditor’s report contained qualifications. Management provided responses to these audit modifications in a statement detailing the impact of audit qualifications, which was included in the annual report. Additionally, secretarial auditors shared their remarks for FY26, with management responses incorporated into the Board’s Report.

Governance and leadership updates

The AGM addressed significant changes to the board composition and director remuneration. Members approved the following key appointments and ratifications:

• Reappointment of Whole-Time Director: Mr. Mridul Dhanuka (DIN: 00199441), who retired by rotation, was reappointed as Whole-Time Director via an ordinary resolution.
• New Appointment: Mr. Arjun Dhanuka (DIN: 00454689) was appointed as Whole-Time Director and his remuneration package was approved through a special resolution. He was previously designated as a Non-Executive, Non-Independent Director.
• Cost Auditor Ratification: The remuneration of the Cost Auditor for FY27 was ratified by ordinary resolution.
• Related Party Transactions: Approval was granted for material related party transactions with Otsuka Chemical (India) Private Limited. Due to potential interest conflicts, Chairmanship for this specific agenda item was temporarily transferred to Independent Director CA (Dr.) Manoj Kumar Goyal.

Meeting proceedings and attendance

The meeting commenced at 12:00 noon IST and concluded at 12:43 pm IST. Thirty-two members participated through video conferencing. Managing Director Manish Dhanuka served as Chairman, having been appointed due to the absence of Non-Executive Chairman Ram Gopal Agarwal. Other directors present included Whole-Time Director Arjun Dhanuka, Independent Directors CA (Dr.) Manoj Kumar Goyal, Shubha Singh, and Tanu Singla.

Key officials in attendance included Company Secretary Kapil Dayya, Chief Financial Officer Sunil Kumar Gupta, and Vice-President Finance Nishant Dalal. Representatives from statutory auditors Singhi & Co., secretarial auditors S. Dhanapal & Associates LLP, and scrutinizer M/s. P Muthukumaran & Associates were also present.

Voting and disclosure

Members exercised their voting rights through e-voting during the meeting. The company stated that e-voting results, along with the scrutinizer’s report, would be declared within two working days of the meeting’s conclusion. These results will be published on the company’s website, NSDL, and submitted to stock exchanges.

Orchid Pharma Limited listed 4,45,86,052 equity shares on the National Stock Exchange of India (NSE) and BSE Limited from September 23, 2026. This listing follows the allotment of shares pursuant to a scheme of amalgamation sanctioned by the National Company Law Tribunal (NCLT), Chennai Bench.

The company issued an intimation under Regulation 30 of the SEBI Listing Regulations to both exchanges. The filing confirmed that the equity shares have been admitted to dealings effective from the specified date.

Regulatory compliance and allotment details

The allotment was executed in continuation of an earlier intimation dated August 1, 2026. The company cited SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as part of its regulatory framework for this disclosure.

Kapil Dayya, Company Secretary and Compliance Officer, signed the digital submission confirming the listing status for both exchanges.

Listing summary